Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg (equivalent: rivastigmine, qty 6 mg) - capsule, hard - excipient ingredients: iron oxide red; hypromellose; gelatin; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; magnesium stearate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; potassium hydroxide; ammonia; pharmaceutical glaze - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg (equivalent: rivastigmine, qty 4.5 mg) - capsule, hard - excipient ingredients: colloidal anhydrous silica; iron oxide red; iron oxide yellow; microcrystalline cellulose; magnesium stearate; gelatin; hypromellose; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid; purified water; industrial methylated spirit; lecithin; 2-ethoxyethanol; dimeticone - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg (equivalent: rivastigmine, qty 3 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; hypromellose; magnesium stearate; titanium dioxide; iron oxide red; iron oxide yellow; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; potassium hydroxide; ammonia; pharmaceutical glaze - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg (equivalent: rivastigmine, qty 1.5 mg) - capsule, hard - excipient ingredients: gelatin; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; iron oxide red; ethanol absolute; potassium hydroxide; ammonia; pharmaceutical glaze - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - rivastigmine hydrogen tartrate - capsules hard - 1.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - rivastigmine hydrogen tartrate - capsules hard - 3 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - rivastigmine hydrogen tartrate - capsules hard - 4.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - rivastigmine hydrogen tartrate - capsules hard - 6 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 3.2 mg/ml (equivalent: rivastigmine, qty 2 mg/ml) - oral liquid, solution - excipient ingredients: citric acid; sodium citrate dihydrate; purified water; sodium benzoate; quinoline yellow - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - exelon is indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). exelon is indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pd). exelon is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)] - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of exelon in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2-4 times the maximum recommended human dose (mrhd) (see data) . the background risk of major birth d